Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Gynecologic Cancer Specialty Channel

Gynecologic Cancer
Specialty Channel
News
Tisotumab Vedotin Improved Efficacy Among Patients With Recurrent or Metastatic Cervical Cancer
07/16/2024
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the...
07/16/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
Allison Casey
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
06/17/2024
Allison Casey
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Nimotuzumab Plus Concurrent Chemoradiotherapy Improved Response, Survival for Patients With Locally Advanced Cervical Cancer
06/12/2024
Allison Casey
According to results from a phase 3 study, the addition of nimotuzumab to concurrent chemoradiotherapy improved response rates and progression-free survival among patients with locally advanced cervical cancer.
According to results from a phase 3 study, the addition of nimotuzumab to concurrent chemoradiotherapy improved response rates and progression-free survival among patients with locally advanced cervical cancer.
According to results from a...
06/12/2024
Oncology
Conference Coverage
Neoadjuvant Sintilimab Plus Chemotherapy Shows Promising Activity Among Patients With Locally Advanced Cervical Cancer
06/03/2024
Allison Casey
According to phase 2 data, sintilimab plus paclitaxel and cisplatin in the neoadjuvant setting showed encouraging antitumor activity among patients with locally advanced cervical cancer.
According to phase 2 data, sintilimab plus paclitaxel and cisplatin in the neoadjuvant setting showed encouraging antitumor activity among patients with locally advanced cervical cancer.
According to phase 2 data,...
06/03/2024
Oncology
Conference Coverage
Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer
06/03/2024
Allison Casey
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be...
06/03/2024
Oncology
Conference Coverage
Chemoradiotherapy Plus Adjuvant Chemotherapy for High-Risk Cervical Cancer After Radical Hysterectomy
06/03/2024
Allison Casey
According to a phase 3 trial, systemic chemotherapy after chemoradiotherapy did not improve disease-free survival or overall survival for patients with cervical cancer with high-risk factors after hysterectomy.
According to a phase 3 trial, systemic chemotherapy after chemoradiotherapy did not improve disease-free survival or overall survival for patients with cervical cancer with high-risk factors after hysterectomy.
According to a phase 3 trial,...
06/03/2024
Oncology
Conference Coverage
Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer
06/02/2024
Allison Casey
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study...
06/02/2024
Oncology
FDA Approval
FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
05/01/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase...
05/01/2024
Oncology
News
Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma
04/23/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG...
04/23/2024
Oncology

Advertisement

News

News
Tisotumab Vedotin Improved Efficacy Among Patients With Recurrent or Metastatic Cervical Cancer
07/16/2024
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the...
07/16/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
Allison Casey
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
06/17/2024
Allison Casey
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Nimotuzumab Plus Concurrent Chemoradiotherapy Improved Response, Survival for Patients With Locally Advanced Cervical Cancer
06/12/2024
Allison Casey
According to results from a phase 3 study, the addition of nimotuzumab to concurrent chemoradiotherapy improved response rates and progression-free survival among patients with locally advanced cervical cancer.
According to results from a phase 3 study, the addition of nimotuzumab to concurrent chemoradiotherapy improved response rates and progression-free survival among patients with locally advanced cervical cancer.
According to results from a...
06/12/2024
Oncology
Conference Coverage
Neoadjuvant Sintilimab Plus Chemotherapy Shows Promising Activity Among Patients With Locally Advanced Cervical Cancer
06/03/2024
Allison Casey
According to phase 2 data, sintilimab plus paclitaxel and cisplatin in the neoadjuvant setting showed encouraging antitumor activity among patients with locally advanced cervical cancer.
According to phase 2 data, sintilimab plus paclitaxel and cisplatin in the neoadjuvant setting showed encouraging antitumor activity among patients with locally advanced cervical cancer.
According to phase 2 data,...
06/03/2024
Oncology
Conference Coverage
Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer
06/03/2024
Allison Casey
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be...
06/03/2024
Oncology
Conference Coverage
Chemoradiotherapy Plus Adjuvant Chemotherapy for High-Risk Cervical Cancer After Radical Hysterectomy
06/03/2024
Allison Casey
According to a phase 3 trial, systemic chemotherapy after chemoradiotherapy did not improve disease-free survival or overall survival for patients with cervical cancer with high-risk factors after hysterectomy.
According to a phase 3 trial, systemic chemotherapy after chemoradiotherapy did not improve disease-free survival or overall survival for patients with cervical cancer with high-risk factors after hysterectomy.
According to a phase 3 trial,...
06/03/2024
Oncology
Conference Coverage
Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer
06/02/2024
Allison Casey
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study...
06/02/2024
Oncology
FDA Approval
FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
05/01/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase...
05/01/2024
Oncology

Interactive Features

Quiz
Pembrolizumab Plus Chemotherapy and Bevacizumab vs Placebo in Patients With Cervical Cancer
11/07/2022
Did patients with cervical cancer experience prolonged PFS and OS when treated with pembrolizumab plus chemotherapy and bevacizumab compared to patients treated with placebo?
Did patients with cervical cancer experience prolonged PFS and OS when treated with pembrolizumab plus chemotherapy and bevacizumab compared to patients treated with placebo?
Did patients with cervical...
11/07/2022
Oncology
Test Your Knowledge
Quiz: Is LGSOC Generally Resistant to Chemotherapy?
08/27/2021
True or false: LGSOC comprises 6% to 8% of all ovarian cancers and generally resists chemotherapy with a median survival of approximately 10 years.
True or false: LGSOC comprises 6% to 8% of all ovarian cancers and generally resists chemotherapy with a median survival of approximately 10 years.
True or false: LGSOC comprises...
08/27/2021
Oncology
doc
Test Your Knowledge
Quiz: Upfront MGPT vs Tumor Screening for Lynch Syndrome in Endometrial Cancer
06/02/2021
True or False: Upfront multi-gene panel testing in patients with endometrial cancer has been shown to detect cases of Lynch syndrome not identified by tumor screening.
True or False: Upfront multi-gene panel testing in patients with endometrial cancer has been shown to detect cases of Lynch syndrome not identified by tumor screening.
True or False: Upfront...
06/02/2021
Oncology
Test Your Knowledge
Quiz: A Common Thread in Rising Endometrial Cases in US Women
05/29/2021
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in...
05/29/2021
Oncology
Test Your Knowledge
Quiz: Is Upfront Germline Genetic Testing Encouraged in Endometrial Cancer?
05/28/2021
True or False: Experts opine that upfront germline genetic testing should be considered for patients with any and all solid tumors, including endometrial cancer.
True or False: Experts opine that upfront germline genetic testing should be considered for patients with any and all solid tumors, including endometrial cancer.
True or False: Experts opine...
05/28/2021
Oncology
Test Your Knowledge
Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?
05/28/2021
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings...
05/28/2021
Oncology
Test Your Knowledge
Quiz: Which Therapy Extended PFS for Ovarian Cancer in the ARIEL3 Study?
10/08/2020
According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
According to the ARIEL3 study,...
10/08/2020
Oncology
Test Your Knowledge
Quiz: Does Pembrolizumab Yield Promising Results in Advanced Urothelial Cancer?
09/10/2020
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or False: Pembrolizumab...
09/10/2020
Oncology
Test Your Knowledge
Quiz: Long-Term Maintenance Olaparib for BRCA-Mutated, Relapsed Ovarian Cancer?
06/25/2020
True or false: Maintenance olaparib did not provide a significant OS improvement in a phase 3 study of patients with platinum-sensitive, BRCA-mutated, relapsed ovarian cancer.
True or false: Maintenance olaparib did not provide a significant OS improvement in a phase 3 study of patients with platinum-sensitive, BRCA-mutated, relapsed ovarian cancer.
True or false: Maintenance...
06/25/2020
Oncology
Test Your Knowledge
Quiz: Does Maintenance Pazopanib Improve OS for Advanced Ovarian Cancer?
05/22/2020
True or false: Maintenance pazopanib improved overall survival in advanced ovarian cancer in a phase 3 clinical trial.
True or false: Maintenance pazopanib improved overall survival in advanced ovarian cancer in a phase 3 clinical trial.
True or false: Maintenance...
05/22/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Tisotumab Vedotin Improved Efficacy Among Patients With Recurrent or Metastatic Cervical Cancer
07/16/2024
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the innovaTV 301 trial, tisotumab vedotin significantly improved efficacy outcomes compared to chemotherapy in the second-or third-line setting among patients with recurrent or metastatic cervical cancer.
According to results from the...
07/16/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
Allison Casey
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
06/17/2024
Allison Casey
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Based on results from the phase...
06/17/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer
06/02/2024
Allison Casey
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.
The phase 2 KEYVIBE-005 study...
06/02/2024
Oncology
FDA Approval
FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
05/01/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase...
05/01/2024
Oncology
News
Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma
04/23/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG...
04/23/2024
Oncology
News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
FDA Approval
FDA Approves Mirvetuximab Soravtansine for Patients With FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2024

Stephanie Holland 

Stephanie Holland 
The FDA has approved mirvetuximab soravtansine for previously treated patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, as detected by an FDA-approved test.
The FDA has approved mirvetuximab soravtansine for previously treated patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, as detected by an FDA-approved test.
The FDA has approved...
03/25/2024
Oncology
FDA Approval
FDA Approves Pembrolizumab Plus Chemoradiotherapy for Patients With Stage III to IVA Cervical Cancer
01/15/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the KEYNOTE-A18 trial, the FDA has approved pembrolizumab plus chemoradiotherapy for patients with FIGO 2014 Stage III to IVA cervical cancer.
Based on results from the KEYNOTE-A18 trial, the FDA has approved pembrolizumab plus chemoradiotherapy for patients with FIGO 2014 Stage III to IVA cervical cancer.
Based on results from the...
01/15/2024
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement